Otsuka (OTCMKTS:OTSKY) Reaches New 52-Week High After Analyst Upgrade

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price hit a new 52-week high during mid-day trading on Wednesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating. The company traded as high as $36.34 and last traded at $36.29, with a volume of 1949 shares. The stock had previously closed at $35.37.

Other research analysts have also issued reports about the company. The Goldman Sachs Group lowered Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. UBS Group raised Otsuka to a “hold” rating in a research report on Tuesday, January 27th. Finally, Morgan Stanley raised Otsuka to an “overweight” rating in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold”.

Otsuka Trading Down 1.6%

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The firm’s fifty day moving average price is $32.87 and its 200-day moving average price is $29.69. The company has a market cap of $38.46 billion and a price-to-earnings ratio of 15.57.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.